Art

J-GLOBAL ID：201102251769337191   Reference number：11A1820200

Clinical Outcome and Prognostic Factors of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma in General Clinical Practice

一般診療における日本人の進行性腎細胞癌患者に対するソラフェニブの臨床アウトカムと予後因子

Author (12)： TANIGAWA Go (Osaka General Medical Center Hospital, Osaka) ,  KAWASHIMA Atsunari (Osaka Univ. Graduate School of Medicine, Osaka) ,  YAMAGUCHI Seiji (Osaka General Medical Center Hospital, Osaka) ,  NISHIMURA Kazuo (Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka) ,  MIYOSHI Susumu (Osaka Rosai Hospital, Osaka) ,  KAJIKAWA Jiro (Sakai Municipal Hospital, Sakai) ,  MEGURO Norio (Toyonaka Municipal Hospital, Toyonaka) ,  YOSIOKA Toshiaki (Sumitomo Hospital, Osaka) ,  OKA Toshitsugu (National Hospital Organization Osaka National Hospital, Osaka) ,  HARA Tsuneo (Ikeda Municipal Hospital, Ikeda, JPN) ,  TAKAYAMA Hitoshi (Osaka Univ. Graduate School of Medicine, Osaka) ,  NONOMURA Norio (Osaka Univ. Graduate School of Medicine, Osaka)
Material： Japanese Journal of Clinical Oncology  (JJCO)
Volume： 41  Issue： 11  Page： 1265-1270  Publication year： Nov. 2011 
JST Material Number： W2222A  ISSN： 0368-2811  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Advanced renal cell carcinoma ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A1820200&from=J-GLOBAL&jstjournalNo=W2222A") }}

JST classification (2)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Sorafenib

Reference (16)：

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
• Reuter VE, Presti JC, Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000; 27: 124-37.
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.
• Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34.

Terms in the title (7)： 一般診療 ,  日本人 ,  進行性腎細胞癌 ,  患者 ,  ソラフェニブ ,  臨床アウトカム ,  予後因子